Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

P A Vasey, R Atkinson, R Coleman, M Crawford, M Cruickshank, P Eggleton, D Fleming, J Graham, D Parkin, J Paul, N S Reed, S B Kaye, P A Vasey, R Atkinson, R Coleman, M Crawford, M Cruickshank, P Eggleton, D Fleming, J Graham, D Parkin, J Paul, N S Reed, S B Kaye

Abstract

A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic-IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139 eligible patients (Pts) (median age 56 years, range 28-85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m(2)); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79%) completed 6 cycles; 17 (12%) stopped due to toxicity. 104 patients (75%) had CTC grade IV neutropenia, and 5 patients (4%) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6%) experienced grade II-III neurotoxicity (all sensory; no motor > grade I). The maximum tolerated dose was reached in cohorts 4 and 5, and the dose limiting toxicities were myelosuppression and diarrhoea. The overall response rate for the study was 66% (49/74); CA125 response was 75% (70/93). Median progression-free survival was 16.6 months (95% CI 13.3-19.1). Recommended doses are carboplatin AUC 5 (via(51)Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m(2). A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment.

Copyright 2001 Cancer Research Campaign.

References

    1. Nat Med. 1996 Sep;2(9):1035-7
    1. Nat Med. 1996 Sep;2(9):1033-5
    1. Semin Oncol. 1996 Oct;23(5 Suppl 12):48-54
    1. Br J Cancer. 1997;75(2):287-94
    1. Br J Cancer. 1997;75(3):417-22
    1. Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-34-S2-37
    1. J Clin Oncol. 1997 May;15(5):1953-64
    1. Ann Oncol. 1997 Apr;8(4):351-4
    1. Ann Oncol. 1997 Apr;8(4):355-61
    1. Oncogene. 1997 Jul 3;15(1):45-52
    1. Eur J Cancer. 1997 Apr;33(4):592-5
    1. Cancer Chemother Pharmacol. 1998;41(2):161-6
    1. Eur J Cancer. 1997 Nov;33(13):2167-70
    1. Br J Cancer. 1998 May;77(10):1686-8
    1. Br J Cancer. 1998 Dec;78(11):1479-87
    1. Oncogene. 1999 Apr 8;18(14):2335-41
    1. J Clin Oncol. 1999 Jul;17(7):2069-80
    1. J Natl Cancer Inst. 2000 May 3;92(9):699-708
    1. Clin Sci. 1969 Aug;37(1):169-80
    1. Cancer. 1981 Jan 1;47(1):207-14
    1. J Clin Oncol. 1989 Nov;7(11):1748-56
    1. J Clin Oncol. 1991 Jul;9(7):1138-50
    1. Cancer. 1993 Jan 15;71(2 Suppl):517-23
    1. J Natl Cancer Inst Monogr. 1993;(15):107-15
    1. J Clin Oncol. 1995 Mar;13(3):726-32
    1. Diabet Med. 1994 Nov;11(9):872-6
    1. N Engl J Med. 1996 Jan 4;334(1):1-6
    1. Neurology. 1996 Jan;46(1):104-8
    1. Neurology. 1996 Jan;46(1):108-11
    1. J Clin Oncol. 1996 May;14(5):1545-51
    1. Cancer Res. 1996 Feb 15;56(4):689-93
    1. J Clin Oncol. 1996 Jun;14(6):1895-902
    1. Anticancer Drugs. 1996 Aug;7 Suppl 2:17-9

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe